16. Crow-Fukase syndrome
12 clinical trials,   18 drugs   (DrugBank: 8 drugs),   5 drug target genes,   79 drug target pathways
Searched query = "Crow-Fukase syndrome", "POEMS syndrome", "Polyneuropathy, organomegaly, endocrinopathy, m-protein, and skin changes syndrome", "Takatsuki disease", "PEP syndrome", "Polyneuropathy, endocrinopathy, plasma cell dyscrasia syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04396496 (ClinicalTrials.gov) | September 22, 2020 | 15/5/2020 | Treatment of POEMS Syndrome With Daratumumab | A Phase II Trial for the Treatment of POEMS Syndrome With Daratumumab | POEMS Syndrome | Drug: Daratumumab Injection | University of Arkansas | Janssen Scientific Affairs, LLC | Recruiting | 18 Years | N/A | All | 10 | Phase 2 | United States |